Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Carcinoma 1

Interventions

Radiotherapy 8Cisplatin 8Cetuximab 8pembrolizumab 5Fluorouracil 5Drug Therapy 5Surveys and Questionnaires 4Celecoxib 4Radiotherapy, Intensity-Modulated 3Radiation 3Sentinel Lymph Node Biopsy 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Physical Therapy Modalities 2Nicotine 2Interviews as Topic 2Injections 2Immunohistochemistry 2High-Energy Shock Waves 2Counseling 2Chemoradiotherapy 2Bupropion 2Aminolevulinic Acid 2trametinib 1traY protein, E coli 1toripalimab 1sodium thiosulfate 1sargramostim 1motexafin gadolinium 1mogamulizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Mouth Neoplasms × (225)Ac-DOTA-c(RGDyK) × Clear all
NCT03258554 2026-06-02

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡